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OPEN
REVIEW
Epstein Barr virus-associated lymphoproliferative
diseases: the virus as a therapeutic target
Eric Tse and Yok-Lam Kwong
Epstein Barr virus (EBV)-associated lymphoproliferative diseases (LPDs) express all EBV latent antigens (type III latency) in
immunodeﬁcient patients and limited antigens (type I and II latencies) in immunocompetent patients. Post-transplantation
lymphoproliferative disease (PTLD) is the prototype exhibiting type III EBV latency. Although EBV antigens are highly
immunogenic, PTLD cell proliferation remains unchecked because of the underlying immunosuppression. The restoration of
anti-EBV immunity by EBV-speciﬁc T cells of either autologous or allogeneic origin has been shown to be safe and effective
in PTLDs. Cellular therapy can be improved by establishing a bank of human leukocyte antigen-characterized allogeneic
EBV-speciﬁc T cells. In EBV+ LPDs exhibiting type I and II latencies, the use of EBV-speciﬁc T cells is more limited, although
the safety and efﬁcacy of this therapy have also been demonstrated. The therapeutic role of EBV-speciﬁc T cells in EBV+ LPDs
needs to be critically reappraised with the advent of monoclonal antibodies and other targeted therapy. Another strategy involves
the use of epigenetic approaches to induce EBV to undergo lytic proliferation when expression of the viral thymidine kinase
renders host tumor cells susceptible to the cytotoxic effects of ganciclovir. Finally, the prophylactic use of antiviral drugs to
prevent EBV reactivation may decrease the occurrence of EBV+ LPDs.
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INTRODUCTION
Epstein Barr virus (EBV) is the ﬁrst human virus isolated from
a neoplastic disorder.1 EBV infects most humans. The initial
infection may be asymptomatic and often occurs in childhood.
In older individuals, a more ﬂorid clinical syndrome of
infectious mononucleosis may occur.2 Regardless of the initial
manifestation, EBV establishes a lifelong latency in B cells. EBV
exists in an episomal form and is not integrated into the host
cell genome.2 EBV is involved in numerous malignancies
(Table 1), suggesting that it plays an important role in
oncogenesis.
During primary infection, EBV enters the oropharyngeal
epithelial cells. Viral replication leads to infection of naïve B
cells. EBV-infected B cells become lymphoblasts and express
the entire EBV latency gene complex, which consists of at least
10 proteins (which include EBNA1, EBNA2, EBNA3, LMP1,
LMP2 and BARF1) and two small RNAs (type III latency).3
These lymphoblasts are highly immunogenic and are targets of
EBV-speciﬁc cytotoxic T cells. However, when EBV-infected B
cells enter lymphoid follicles, downregulation of these EBV
immunogenic proteins occurs, with the expression of three
less immunogenic EBV proteins (EBNA1, LMP1 and LMP2)
(type II latency) remaining, thereby allowing these EBV-
infected B cells to survive. When memory B cells exit lymphoid
follicles, they may not express EBV-related proteins (type 0
latency). These memory B cells circulate and re-enter
secondary follicles, where they express EBNA1 (type I latency).
EBNA1 promotes the replication of the viral episome.4 The
persistence of EBV-infected B cells of type II latency in these
secondary lymphoid tissues, including the tonsils,5 promotes
the expression of LMP1 and LMP2, which are essential signals
for the survival of these circulating EBV-infected memory
B cells.
A dominant theory in oncogenesis is that when transforma-
tion occurs, neoplastic cells are often arrested at their respective
stages of cellular development or maturation. Transcriptional
programs are often retained, and phenotypes of these neo-
plastic cells often resemble those of their normal counterparts.
This notion is reﬂected in the various EBV latency states in
EBV-associated malignancies (Table 1).
EBV-ASSOCIATED LYMPHOID MALIGNANCIES
The number of EBV-associated lymphoid malignancies con-
tinues to increase (Table 1), emphasizing the importance of
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EBV in lymphomagenesis. EBV-associated lymphoproliferative
diseases (LPDs) can occur both in immunocompetent and
immunocompromised patients. In general, EBV latency states
correlate with immunocompetency. EBV type III latency is
typically found in LPDs developing in immunodeﬁcient sub-
jects, whereas type I and II latencies are observed in LPDs
developing in otherwise immunocompetent subjects.
EBV+ LPDs are highly heterogeneous with regard to
pathology and the host background against which the diseases
arise. Therefore, treatment strategies are also highly variable.6
In general, chemotherapy is the mainstay of treatment in
immunocompetent patients. In B-cell malignancies, the anti-
CD20 monoclonal antibody rituximab is also administered. In
immunodeﬁcient patients, efforts to boost the host immunity
should be attempted ﬁrst. In patients with iatrogenic immu-
nosuppression, including autoimmune diseases or after organ
allografting, decrease or withdrawal of the immunosuppression
constitutes the ﬁrst-line strategy. If the LPDs fail to regress, the
Table 1 Epstein Barr virus-associated malignancies
Neoplasms EBV latency Treatment strategy EBV-targeted
therapy
Lymphoproliferative diseases
B cells
Post-transplantation lymphoproliferative disorders III Reduction of immunosuppressive agents; rituximab +/−
chemotherapy
+++
Lymphoproliferative diseases associated with primary
immune disorders
III Rituximab +/− chemotherapy −
Lymphomas associated with HIV infections III HAART and chemotherapy −
Iatrogenic immunodeﬁciency-associated lymphoproli-
ferative diseases
III Reduction of immunosuppressive agents; rituximab +/−
chemotherapy
−
EBV+ diffuse large B-cell lymphoma of the elderly II Rituximab+CHOP-based chemotherapy −
Diffuse large B-cell lymphomas, not otherwise
speciﬁed
II Rituximab+CHOP-based chemotherapy ++
Pyothorax-associated lymphoma III Rituximab+chemotherapy −
Plasmablastic lymphoma III Rituximab+chemotherapy −
Primary effusion lymphoma I Rituximab+chemotherapy −
Burkitt lymphoma I Intensive chemotherapy +
Hodgkin lymphoma II Combination chemotherapy ++
T cells
Peripheral T-cell lymphoma, not otherwise speciﬁed II Chemotherapy ++
EBV+ lymphoproliferative disorders of childhood I/II Chemotherapy −
Chronic active EBV infection (T-cell type) II Allogeneic HSCT −
NK cells
Extranodal NK/T-cell lymphomas, nasal type II L-asparaginase-based chemotherapy ++
Aggressive NK-cell leukemia II Chemotherapy −
Chronic active EBV infection (NK-cell type) II Allogeneic HSCT −
Epithelial cancers
Nasopharyngeal cancer II Radiotherapy +/− chemotherapy ++
Lymphoepithelioma-like carcinoma II Surgical resection +/− chemotherapy −
Gastric carcinoma I Surgical resection +/− chemotherapy −
Sarcomas and other soft-tissue tumors
Inﬂammatory pseudotumor variant of follicular dendritic
cell sarcoma
II Chemotherapy; surgical resection −
HIV-related smooth muscle tumor III HAART; surgical resection −
Post-transplantation smooth muscle tumor III Reduction of immunosuppressive agents; surgical
resection
−
Congenital immunodeﬁciency-related smooth muscle
tumor
III Surgical resection −
Abbreviations: EBV, Epstein-Barr virus; HIV, human immunodeﬁciency virus; NK cells, natural killer cells.
+++: most experience; ++: some experience; +: limited experience; –: no experience.
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use of chemotherapy is indicated. In patients infected with
human immunodeﬁciency virus, highly active antiviral treat-
ment should also be initiated together with chemotherapy.7
In patients not responding to these traditional approaches,
strategies targeting EBV have been adopted.
CELLULAR THERAPY TARGETING EBV-POSITIVE LPD
WITH EBV IN TYPE III LATENCY
EBV+ neoplastic cells express EBV antigens, which are
potential targets for EBV-speciﬁc cytotoxic T cells. However,
cellular control of EBV-infected cells might not be effective
when the immune system is suppressed. The prototype of this
condition is post-transplantation lymphoproliferative diseases
(PTLDs). This condition can occur after two types of organ
transplantation: allogeneic hematopoietic stem cell transplanta-
tion (HSCT) and solid organ allografting. After allogeneic
HSCT, lymphoid cells are donor-derived. Therefore, PTLDs are
of donor lymphoid origin. After solid organ allografting,
however, lymphoid cells are derived from the recipient. Hence,
PTLDs are of recipient origin.
EBV-POSITIVE PTLD AFTER ALLOGENEIC HSCT
PTLD is an important complication after allogeneic HSCT.8
Risk factors include T-cell depletion, anti-thymocyte globulin
use, unrelated or human leukocyte antigen (HLA)-mismatched
grafts where T-cell depletion or anti-thymocyte globulin is
used, age⩾ 50 years and second HSCT.9 The incidence of
PTLD peaks at 2–3 months, primarily within the ﬁrst 6 months
post HSCT.9 Once developed, PTLD post HSCT is a highly
fatal disorder.
Early detection of EBV+ PTLD offers the best possibility
of cure. In at-risk patients, monitoring circulating EBV DNA
loads enables the early detection of impending EBV+
PTLD.10–12 Once an increasing trend of circulating EBV
DNA is detected, reduction or withdrawal of immunosuppres-
sion should be instituted.8 Because most cases of EBV+ PTLD
post HSCT involve CD20+ B cells, the preemptive use of
rituximab has been shown to abort the development of clinical
disease.8,12,13 However, when PTLD has developed, the use of
rituximab and chemotherapy is less effective. In addition,
mortality remains high, suggesting that alternative approaches
should be pursued.
The earliest evidence that cellular therapy might be effective
for EBV+ PTLD post HSCT was provided by effective disease
control with donor lymphocyte infusion, which re-constituted
the recipient with donor-derived EBV-reactive T cells.14
However, donor lymphocyte infusion exacerbates graft-
versus-host disease and is not always practical in severely ill
patients. Donor lymphocytes may not be available from
matched-unrelated donors and almost certainly cannot be
obtained from cord blood donors.
The production of EBV-speciﬁc cytotoxic T cells provides a
more speciﬁc and potent means of targeting EBV+ PTLD.15
Observations in experimental animals showed that T cells
primed against EBV homed to and induced selective regression
of EBV-infected B cells.16 Furthermore, genetically marked
donor-derived EBV-speciﬁc T cells persist for long durations
and re-constitute immunity against EBV in recipients of
allogeneic HSCT.17 These observations ushered in initial trials
where HSCT recipients either at risk of or who had actually
developed EBV+ PTLD were adoptively transferred with
EBV-speciﬁc T cells.10,18,19 These studies showed that infusions
of donor-derived EBV-speciﬁc T cells were safe and did not
induce graft-versus-host disease.10,18,19 These preliminary
observations were conﬁrmed by two recent studies. In 101
patients who received donor-derived EBV-speciﬁc T cells
prophylactically, none developed PTLD. In 13 patients who
were treated for established EBV+ PTLD, 11 responded to
EBV-speciﬁc T cells.20 In 47 patients with established EBV+
PTLD receiving either donor-derived or third-party EBV-
speciﬁc T cells, an overall response rate of 68% was
achieved.21 Non-respondents harbored EBV strains that
differed from those against which the T cells were primed.
In one exceptional case, the PTLD was recipient-derived,
so that donor-derived T cells were ineffective owing to HLA
restriction.21
The key ﬁndings of these studies are that the prophylactic
use of donor-derived EBV-speciﬁc T cells is safe and effective
in allogeneic HSCT patients at high-risk of EBV+ PTLD.
However, the use of cellular therapy has not been compared
with immunotherapy using rituximab, so that its role in
prophylactic settings remains undeﬁned. In patients with
established EBV+ PTLD, wherein treatment with rituximab
and chemotherapy exhibits a low successful outcome,
EBV-speciﬁc T cells can also achieve a high response rate.
EBV-POSITIVE PTLD AFTER SOLID ORGAN
ALLOGRAFTING
PTLD after solid organ allografting occurs considerably later,
typically after the ﬁrst year post-transplantation, although cases
may occur after many years.22 The majority of PTLD cases after
solid organ allografting are derived from B-cell lineage, which
may or may not be EBV+. A minority of cases is derived from
T-cell lineage and is typically EBV-negative.
For EBV+ PTLD after solid organ allografting, a strategy
of decreased immunosuppression followed by the use of
rituximab and chemotherapy currently serves as the standard
approach.23 However, not all patients respond, and alternative
approaches are needed for refractory patients.
Early observations indicated that cellular therapy might be
useful for EBV+ PTLD after solid organ allografting.24,25 These
studies utilized fully or partially HLA-matched allogeneic
T cells. Later studies examined the use of autologous T cells.
In patients with evidence of active EBV infection, prophylactic
infusion of autologous EBV-speciﬁc T cells was safe and
appeared to prevent PTLD.26,27 The use of autologous
EBV-speciﬁc T cells in conjunction with withdrawal of
immunosuppression and immunochemotherapy had also been
shown to be feasible and effective.27,28
Although these studies have indicated that autologous
EBV-speciﬁc T cells are safe, do not cause graft rejection and
may be effective especially when used prophylactically, the
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advent of rituximab and better chemotherapy regimens means
that this strategy is only reserved for patients not responding to
standard approaches.
THE USE OF THIRD-PARTY EBV-SPECIFIC T CELLS
FOR PTLD
The generation of EBV-speciﬁc T cells, either allogeneic or
autologous, requires 8–12 weeks.3 Therefore, the timely treat-
ment of a patient with active disease not responding to
conventional therapy is problematic. Furthermore, in cord
blood or matched-unrelated donor HSCT, donor-derived
T cells are generally not available. In patients after solid organ
allografting treated with immunosuppression, the collection of
enough autologous T cells may not always be feasible.
The use of third-party partially HLA-matched EBV-speciﬁc
T cells has been explored.25 In an early study, eight patients
received EBV-speciﬁc T cells selected on a best HLA-match
basis, with three patients achieving a complete remission.29 A
multicenter study examined 33 patients treated with the same
strategy. The overall response rate was 52% at 6 months.30
Similarly, third-party EBV-speciﬁc T cells have also been used
successfully in PTLD after cord blood transplantation,31
wherein donor-derived T cells could not be obtainable.
The logistics of third-party EBV-speciﬁc T cells has recently
been simpliﬁed by the establishment of a bank of HLA-typed
allogeneic EBV-speciﬁc T cells using good manufacturing
practice standards.32 The clinical utility of such a bank remains
to be deﬁned.
CELLULAR THERAPY TARGETING EBV+ LPD WITH EBV
OF TYPE I AND II LATENCIES
In conditions other than organ allografting where severe
immunosuppression is not involved, EBV is present in type I
and II latencies. Although some EBV antigens are expressed,
neoplastic cells might have evaded the innate host immune
response. Adoptive transfer of a population of EBV-reactive
cytotoxic T cells may potentially provide cellular control of the
neoplastic cells.
In LPD with EBV of type I and II latencies, only a limited
number of EBV antigens are expressed on the neoplastic cells.
Therefore, the efﬁcacy of EBV-speciﬁc T cells is not expected to
be as good as for PTLD. Experiments in vitro had shown that
cloning of T cells reactive to LMP1 and LMP2, which are
generally expressed in type II latency in Hodgkin lymphoma,
could be achieved.33 The clinical feasibility of such an
approach was subsequently demonstrated, where autologous
EBV-speciﬁc T cells generated ex vivo from patients with EBV+
Hodgkin lymphoma were shown to persist to up to 13 weeks
in vivo.18 These observations were later conﬁrmed in a larger
number of patients,34 suggesting that autologous EBV-speciﬁc
T cells is potentially effective in selected patients with relapsed
EBV+ Hodgkin lymphoma.
In chronic active EBV infection, which is another disease
that typically involves EBV in type II latency, the infusion of
autologous EBV-speciﬁc T cells led to an objective response in
four of ﬁve patients.35
More recently, the above observations were replicated in
patients with EBV+ lymphomas of various histopathologic
Table 2 Cellular therapies for Epstein Barr virus-associated lymphoproliferative diseases
Type of cellular
therapy
Disease Advantages Limitations
DLI PTLD after allogeneic HSCT Available from most sibling donors
Complicated manufacturing process
not required
Development of GVHD
Generally not available from MUD and UCB
Donor EBV-speciﬁc
T cells
PTLD after allogeneic HSCT Available from most sibling donors
Not associated with GVHD
Generally available from MUD and UCB
Complicated and time-consuming process of
manufacturing EBV-speciﬁc cytotoxic T cells
from individual donors
Autologous EBV-
speciﬁc T cells
PTLD after solid organ
transplantation
Not associated with graft rejection
No issue with HLA matching
Complicated and time-consuming manufactur-
ing process
EBV-speciﬁc cytotoxic T cells
Long-term persistence of EBV-speciﬁc cytotoxic
T cells may not be achievable with continued
immunosuppression
Third party EBV-
speciﬁc cytotoxic
T cells
PTLD after allogeneic HSCT, UCB
HSCT and solid organ transplantation
Not associated with GVHD
Less time-consuming if a bank of
allogeneic EBV-transformed
lymphoblastoid cell lines available
A bank of allogeneic EBV-transformed lympho-
blastoid cell lines required
HLA may not be fully matched
Autologous EBV-
speciﬁc T cells
EBV-lymphoproliferative diseases
with type II or III EBV latencies
Not associated with GVHD Genetic engineering of EBV-transformed
lymphoblastoid cell lines required
Abbreviations: DLI, donor lymphocyte infusion; EBV, Epstein-Barr virus; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell
transplantation; MUD, matched unrelated donor; PTLD, post-transplantation lymphoproliferative diseases; UCB, umbilical cord blood.
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subtypes.36 In 20 patients with relapsed EBV+ lymphomas,
complete responses were observed in 4 of 6 NK/T-cell
lymphoma cases, 3 of 8 Hodgkin lymphoma cases, 2 of
4 cases of diffuse large B-cell lymphoma and 1 PTLD case.
Because all of these lymphomas harbored type II latency EBV,
the results indicate that EBV-speciﬁc T cells are also
effective for LPDs not expressing highly immunogenic EBV
antigens, as observed in malignancies involving type III
latency EBV.
Although these results are exciting, they must be
considered in the context of other targeted therapies for
these lymphomas (Table 2). Furthermore, the complicated
logistics of manufacturing EBV+ autologous T cells may
limit the use of this form of treatment outside of clinical
trials.
METHYLATION OF EBV GENOME AS A POTENTIAL
THERAPEUTIC TARGET
In EBV-infected cells, the virus utilizes the expression of several
different gene programs to control the expression of proteins
on the infected cells. The regulation of expression is controlled
by various epigenetic modiﬁcations to histone and DNA in the
EBV genome.37 Methylation of the CpG islands of the major
EBV latency promoter occurs in circulating EBV+ memory B
cells, leading to type I latency.38 Similarly, CpG methylation of
the EBV promoters also occurs in Burkitt lymphoma (type I
latency) and Hodgkin lymphoma (type II latency).39 These
epigenetic alterations suppress the expression of highly immu-
nogenic EBV proteins characteristically found in the viral lytic
phase, so that EBV-infected cells are able to evade immuno-
surveillance mechanisms.40
Epigenetic changes in the EBV genome may also indirectly
lead to epigenetic alterations of EBV-infected cells. EBNAs
and LMPs interact with many proteins involved in
controlling host cell DNA and histone modiﬁcations.40 In
neoplastic cells, these epigenetic changes repress the production
of key tumor suppressors and contribute to the malignant
phenotype.
The understanding of the epigenetic control of the latent-
lytic switch in the EBV genome provides the theoretical
framework of the ‘lytic-induction therapy.’40 In this approach,
drugs that potentially reverse epigenetic changes in the EBV
genome are postulated to induce the virus to undergo lytic
phase proliferation in tumor cells, thereby leading to the
expression of viral thymidine kinase. Therefore, when the
antiviral drug ganciclovir is administered, it is phosphorylated
by the viral thymidine kinase and subsequently becomes toxic
to the neoplastic cell containing the lytic virus.41 This concept
had been tested in 15 patients with PTLD, B-cell, T-cell,
NK-cell and Hodgkin lymphoma.42 Ten patients showed
signiﬁcant antitumor responses, and four patients achieved
complete remission.
Another interesting observation was that the chemothera-
peutic drug cyclophosphamide appeared to induce viral lytic
phase in endemic Burkitt lymphoma.43 On the basis of this
proposition, a phase I study recently evaluated the concomitant
use of valacyclovir and cyclophosphamide in endemic Burkitt
lymphoma and showed that this combination was safe.44
Further clinical testing of this concept is needed.
Although these results appear promising, they must be
compared with emerging novel and targeted therapies for these
lymphomas.
ANTIVIRAL TREATMENT IN EBV+ LPD
Except when used together with epigenetically active
agents,41–44 antiviral drugs exhibit no direct effect on EBV+
LPD. However, when used prophylactically, antiviral drugs
appear to suppress EBV replication and hence decrease the
occurrence of PTLD after HSCT or solid organ
allografting.45–48 Antiviral drugs also appear to be effective in
suppressing EBV replication in immunocompetent
subjects.49–51 Hence, in patients at high risk of EBV+ PTLD,
the use of prophylactic antiviral drugs may be warranted.
CONCLUSIONS
In EBV+ LPD, EBV is an attractive therapeutic target.
Cellular therapy targeting EBV is an important validation
of the efﬁcacy of the immune system against neoplastic
cells. However, these strategies must be compared with the
emerging availability of gene- or pathway-targeted therapies.
Finally, the production of EBV-speciﬁc T cells must
be streamlined to attain a more timely and affordable
treatment.
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